Panel reactive antibodies in post-kidney transplantation

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Panel reactive antibodies (PRA) are critical indicators of immune sensitization in kidney transplant candidates.
• Understanding the clinical relevance of PRA, particularly post-kidney transplantation (KT), is essential for managing patient outcomes.

Purpose of the Study:

• To evaluate the clinical significance of panel reactive antibodies (PRA) in patients following kidney transplantation (KT).
• To assess the correlation between pre- and post-transplant PRA levels and the occurrence of rejection episodes or graft failure.

Main Methods:

• Analysis of 90 kidney transplant recipients, including living related and cadaveric transplants.
• Evaluation of pre-KT and post-KT panel reactive antibody levels (PRA-T and PRA-B).
• Correlation of PRA levels with rejection episodes, graft failure (GF), and donor-specific HLA antibodies.

Main Results:

• A low percentage of patients (2.89%) with no rejection had high pre-KT PRA (>80%).
• Significantly higher PRA-T and PRA-B levels were observed in post-KT rejections (28.57% and 33.3%, respectively).
• None of the graft failure cases from chronic rejection had high pre-KT PRA (<20%), but one had high post-KT PRA-T (80%). No donor-specific HLA antibodies were detected.

Conclusions:

• Elevated post-KT PRA levels, even without detectable donor-specific HLA antibodies, suggest ongoing immunological reactions.
• Increased PRA post-transplant is a potential indicator of immunological risk, correlating with graft failure.
• Monitoring PRA levels after kidney transplantation is clinically relevant for predicting and managing immunological complications.